Effect of lamivudine on survival rate of patients with chronic severe hepatitis B

张南; 夏杰; 邓国宏; 王宇明

您当前的位置：

首页 >

文章列表页 >

Effect of lamivudine on survival rate of patients with chronic severe hepatitis B

更新时间：2026-01-09

- Effect of lamivudine on survival rate of patients with chronic severe hepatitis B
- Journal of Army Medical University Vol. 30, Issue 1, Pages: 75-77(2008)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R195.4;R512.62;R975.5
- Published：2008
- 稿件说明：
移动端阅览
张南,夏杰,邓国宏,王宇明.拉米夫定对慢性重型乙型肝炎患者生存率的提高[J].陆军军医大学学报(原第三军医大学学报),2008,30(01):75-77.

　ZHANG Nan,XIA Jie,DENG Guo-hong,WANG Yu-ming.Effect of lamivudine on survival rate of patients with chronic severe hepatitis B[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(01):75-77.
张南,夏杰,邓国宏,王宇明.拉米夫定对慢性重型乙型肝炎患者生存率的提高[J].陆军军医大学学报(原第三军医大学学报),2008,30(01):75-77. DOI：

　ZHANG Nan,XIA Jie,DENG Guo-hong,WANG Yu-ming.Effect of lamivudine on survival rate of patients with chronic severe hepatitis B[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(01):75-77. DOI：

摘要

目的观察抗病毒药物拉米夫定对慢性重型乙型病毒性肝炎患者生存率的影响。方法采用配对的回顾性队列研究方法，对1999年10月至2003年12月住院的慢性重型乙型病毒性肝炎患者，根据年龄、性别和病程3个变量对应用拉米夫定和未用拉米夫定治疗的患者进行匹配，比例为1∶1。配对结果为拉米夫定治疗组103例，未用拉米夫定组103例。对研究对象进行随访并比较两组中位生存时间及生存率的差别。结果拉米夫定治疗组中位生存时间为85 d，3年生存率为42.7%；未用拉米夫定组中位生存时间为35 d，3年生存率为23.4%，两组之间生存率有明显差异（P0.01）。结论应用拉米夫定治疗可提高慢性重型乙型病毒性肝炎患者的生存率。

Abstract

Objective To investigate the survival rate of patients with chronic severe hepatitis B (CSH) after lamivudine treatment. Method A matched retrospective cohort study using data on patients derived from a prospectively collected chronic severe hepatitis B database was conducted. The database included patients who received or did not receive lamivudine treatment from October

1999 to December

2003. The match was conducted according with 3 variables: sex

age and duration of disease. The match ratio was 1∶1. Cases were patients who received lamivudine treatment (n=103).Controls were patients who did not receive lamivudine treatment (n=103). All the patients were followed up and their median survival time and survival rate were compared and evaluated. Results The median survival time in lamivudine treatment group and control group were 85 and 35 d respectively. The survival rate for 3 years in treatment group and control group were 42.7% and 23.4% respectively. There was significance difference in survival rate between the 2 groups (P0.01). Conclusion Lamivudine may improve survival of patients with chronic severe hepatitis B.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy of lamivudine in treatment on HBV-related liver failure：Meta analysis study

Expression of GLIS3 protein in triple negative breast cancer and its influence on prognosis of patients

A novel estrogen receptor expression stratification (low/moderate/high) based on Chinese population provides more accurate prognosis prediction for HR⁺/HER2^- early breast cancer patients

Immunosuppressive microenvironment of TGIF1-overexpressing gastric cancers and its clinical significance

Impact of molecular heterogeneity of NPM1 mutations on prognosis of acute myeloid leukemia: a clinical report of 86 cases

Related Author

张耀

郑莎

周吉军

王宇明

李晨浩

刘月平

李春晓

崔国忠

Related Institution

Department of Breast and Thyroid Surgery， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Gastroenterology， Chongqing Hechuan District People’s Hospital

School of Medicine， Chongqing University

Chongqing Key Laboratory of Precision Prevention and Treatment for Digestive System Tumors， Department of Gastroenterology， Army Medical Center of PLA/Daping Hospital of Third Military Medical University

Department of Hematology, the First Hospital of Lanzhou University

⁰